

QUIZ

11/11/2024

Dr Kishore S Dharan
Consultant Nephrologist
MOSC Medical College, Kolenchery

All are true about empagliflozin except

- 1.Increases serum magnesium levels
- 2.Increases serum phosphate levels
- 3.Increases Hemoglobin levels
- 4.Increases serum uric acid level

Answer : 4

SGLT2 INHIBITORS –

-**Increase S Mg levels** by a class effect, especially in patients with hypomagnesemia.- increases both transcellular and paracellular reabsorption in the kidney as well as intestinal reabsorption

Magnesium Homeostasis: A Review Shah, Chintan V. et al.American Journal of Kidney Diseases, Volume 83, Issue 5, 648 – 658

Sodium/Glucose Cotransporter 2 Inhibitors and

-**increase tubular reabsorption of phosphate**, thereby increasing serum phosphate levels

-**increase hemoglobin levels** mainly by stimulating endogenous EPO production and through the stimulation of the HIF pathway

-**lower uric acid by $\approx 0.6-1.5$ mg/dL** by alteration of uric acid transport activity in renal tubule by increased glycosuria

WINNER

Dr.Shilpa Devamare
Govt medical college, Kozhikode

Question No: 2

The true statement about “FLOW” trial with Semaglutide is

1. Both subcutaneous and oral semaglutide were used
2. Showed significant benefit in both high and low renal risk patients
3. Only well controlled Type2 diabetics were included
4. Majority of patients were on RAS and SGLT2 inhibitors

Ans: 2 ; Showed significant benefit in both high and low renal risk patients

Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes

N Engl J Med 2024 May 24

- designed to assess the effect of a GLP-1RA on primary composite kidney outcomes among patients with CKD and type 2 diabetes
- WEEKLY once subcutaneous semaglutide was used
- HBA1c upto 10 were included
- Only 15% were on SGLT2i
- significantly decreased the risk of progression of kidney disease in T2DM

WINNER

Dr. Athulya
Thiruvananthapuram